Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
SEMA6B Biologics Sequence Review Report 2026: Semaphorin-6B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA6B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA4D Biologics Sequence Review Report 2026: Semaphorin-4D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA4G Biologics Sequence Review Report 2026: Semaphorin-4G Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA4B Biologics Sequence Review Report 2026: Semaphorin-4B Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA4A Biologics Sequence Review Report 2026: Semaphorin-4A Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3G Biologics Sequence Review Report 2026: Semaphorin-3G Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3G protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA4C Biologics Sequence Review Report 2026: Semaphorin-4C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA4C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3F Biologics Sequence Review Report 2026: Semaphorin-3F Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3F protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3D Biologics Sequence Review Report 2026: Semaphorin-3D Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3E Biologics Sequence Review Report 2026: Semaphorin-3E Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3E protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SEMA3C Biologics Sequence Review Report 2026: Semaphorin-3C Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SEMA3C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
8 min read
SCARF1 Biologics Sequence Review Report 2026: Scavenger receptor class F member 1 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of SCARF1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
2
3
4
5
>>
1503
>